Insights and Content Hub | Pharmaceutical Launch Excellence Summit

Download your complimentary copy of the industry report today for an in-depth analysis of the trends, challenges and market forces shaping pharmaceutical launches. Explore the latest insights on market access, pricing and reimbursement, AI, launch execution, and evolving regulatory requirements, alongside real-world examples from leading pharmaceutical organisations.

• Why up to two-thirds of pharmaceutical launches fail to meet expectations and the common execution gaps separating launch readiness from launch success.
• How the first 6-12 months now determine long-term launch performance, with early access, adoption and payer decisions becoming increasingly difficult to reverse.
• The impact of the EU HTA Regulation and Joint Clinical Assessments, and what launch teams need to do now to prepare evidence strategies for a changing European market access landscape.
• How pricing, reimbursement and access pressures are reshaping launch strategy across Europe and the US, from Medicare negotiations to increasing payer scrutiny and value-based assessments.
• The rise of obesity, oncology and specialty therapies, with oncology spend forecast to exceed $440 billion globally by 2029 and obesity medicines projected to reach up to $280 billion by 2030.
• Practical AI use cases already improving launch performance, including forecasting, omnichannel optimisation, field enablement, medical insight generation and early signal detection.
• How leading organisations are evolving launch operating models, moving from milestone-based launch planning to continuous launch performance management.
• Real-world lessons from companies including AstraZeneca, Roche, Novartis, Teva and Sandoz on evidence generation, market access, launch sequencing and supply resilience
  

Explore Pharma Launch Excellence: 2025 vs 2026

Discover how pharmaceutical launch strategies are evolving with our latest comparative analysis. This report highlights key market trends, emerging therapeutic areas, and the factors behind launch failures and successes, giving you actionable insights to plan effectively for 2026. Read the full analysis now

AI is rapidly redefining how pharmaceutical companies plan, execute, and optimise drug launches. This exclusive insight brief explores the growing impact of AI (particularly Generative AI) across every stage of the launch lifecycle.

From early discovery to post-launch performance, AI is enabling faster timelines, smarter resource allocation, and more personalised engagement strategies.

Access the Insight Brief now >>

Pharma Launch Readiness Checklist: Your 10-Step Guide to Pharma Launch Success

Is your pharma launch ready? This concise checklist distills the key insights from our 2025 Global State of Pharma Launch Excellence Industry Report into a practical guide for launch leaders, brand teams, and cross-functional stakeholders. Learn how to navigate complexity, avoid common pitfalls, and drive long-term success, from strategy and market entry to post-launch performance. Download your copy now and future-proof your next launch>>

Relive the highlights from the inaugural Pharmaceutical Launch Excellence (PHLEX) Summit in London with our official Post Show Report.

Over 75 pharma launch leaders came together to share strategies on forecasting, cross-functional orchestration, digital transformation, and post-launch optimization. This report captures the key insights, success frameworks, and community energy that defined the event, plus a preview of what’s to come at the 2nd Annual PHLEX Summit this December.

Download your copy now and join the growing #PHLEX community driving better patient outcomes worldwide.

The pharmaceutical landscape is evolving rapidly, with more launches failing than ever before. This brand new report - the most detailed and accurate to date - provides a full update on the current state of pharmaceutical launches, examining why these failures are occurring, which specific launches are struggling, and what strategies companies are implementing to overcome these challenges. This comprehensive analysis names key drugs, organisations, and insights to help you navigate regulatory hurdles and position your launches for success in this evolving landscape. Download your complimentary copy now

Ahead of the Pharmaceutical Launch Excellence Summit, we ran a survey to gain a better understanding of what priorities are shaping launch excellence, from GTM strategy and digital marketing to AI-powered tools driving smarter, faster launches. Get your complimentary infographic now>>

#PHLEXSummit brought together the global launch community, from marketing directors and heads of launch excellence to commercial leaders. Discover who’s attended the Pharmaceutical Launch Excellence Summit in London last December! Download the snapshot of attendees list now

*PLEASE NOTE THAT JOB TITLES AND ORGANIZATIONS HAVE BEEN SEPARATED FOR DATA PROTECTION PURPOSES*

Discover how pharma can move from AI theory to practical implementation in launch strategies. Simone Rebora shares insights on overcoming key barriers, fostering cross-functional collaboration during digital transformation, and building a phased AI roadmap that delivers value at every stage. Plus, hear what he’s most looking forward to at the Pharmaceutical Launch Excellence Summit.

Ahead of the Pharma Launch Excellence Summit, Sherif Elhaw, Former Director, Emerging Markets, Launch Excellence Lead, Former Pfizer explores how pharma launches are shifting toward agile, localised strategies supported by cross-functional collaboration and digital innovation. Check it out below

Join us for a pre-event conversation with Laura Wallace, Former Global Head of Integrated Evidence at Boehringer Ingelheim, as she shares expert insights on designing cross-functional, cross-stakeholder evidence strategies for pharmaceutical launches. Discover how to align evidence needs across regulators, payers, HCPs, and patients, avoid late-stage gaps, and balance global consistency with local market adaptation.

[Speaker Interview] Sherif Elhaw, Director, Emerging Markets, Launch Excellence Lead at Pfizer shares insights on the evolving pharmaceutical launch landscape, emphasizing the importance of innovation, data-driven decision-making, and overcoming cognitive biases for successful product launches.

[Speaker Interview] Paula Albuquerque, Assets Strategic Planning, at UCB shares insights on evolving landscape of launch excellence, highlighting the importance of strategic agility, market access collaboration, and sustainable practices to ensure both corporate success and equitable patient outcomes.

[Speaker Video Interview] Simone Rebora, Global Marketing Director at Ipsen shares insights on building expertise, evolving in the industry, mastering successful launches and adapting global launch strategies.